Literature DB >> 3568270

Chemotherapeutic agents do not interact with neurotransmitter receptors.

S J Peroutka.   

Abstract

The interactions of cisplatin, 5-fluorouracil, doxorubicin, mitomycin, carmustine (BCNU), cyclophosphamide, methotrexate and thio-TEPA were assessed at three neurotransmitter receptor binding sites. Each drug was inactive at concentrations as high as 10(-4) M in displacing the specific binding of 3H-spiperone to dopamine D2, 3H-pyrilamine to histamine H1, and 3H-quinuclidinyl benzilate to muscarinic cholinergic receptors. These data suggest that chemotherapy-induced nausea and vomiting are not due to interactions with neurotransmitter receptors.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3568270     DOI： 10.1007/bf00254564

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  4 in total

1.  Antiemetics: neurotransmitter receptor binding predicts therapeutic actions.

Authors:  S J Peroutka; S H Snyder
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

Review 2.  Neurotransmitter receptor binding and drug discovery.

Authors:  S H Snyder
Journal:  J Med Chem       Date:  1983-12       Impact factor: 7.446

3.  Emesis as a critical problem in chemotherapy.

Authors:  J Laszlo; V S Lucas
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

Review 4.  The control of chemotherapy-induced emesis.

Authors:  L J Seigel; D L Longo
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391
  4 in total
  3 in total

Review 1.  Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear.

Authors:  C Seynaeve; P H De Mulder; J Verweij
Journal:  Pharm Weekbl Sci       Date:  1991-02-22

Review 2.  Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds.

Authors:  C Veyrat-Follet; R Farinotti; J L Palmer
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

3.  Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and alpha 1-adrenergic receptors.

Authors:  J Herrstedt; J Hyttel; J Pedersen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.